Thiazolidinedione usage is associated with decreased response to clopidogrel in DM patients

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 608-610

  Park, Kyung Woo ^a   Kang, Jeehoon ^a   Park, Jin Joo ^a   Yang, Han Mo ^a   Kwon, Yoo Wook ^a   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Clopidogrel; Cytochrome P450 3A enzyme; On treatment platelet reactivity; Thiazolidinedione

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; SULFONYLUREA;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG RESPONSE; HUMAN; LETTER; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; POINT OF CARE TESTING; PRIORITY JOURNAL; SMOKING; STATISTICAL ANALYSIS; THROMBOSIS;

CLOPIDOGREL; CYTOCHROME P450 3A ENZYME; ON-TREATMENT PLATELET REACTIVITY; THIAZOLIDINEDIONE;

AGED; COHORT STUDIES; DIABETES MELLITUS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; THIAZOLIDINEDIONES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84883792908     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.225     Document Type: Article

References (14)

1. T. Hammoud, J.F. Tanguay, and M.G. Bourassa Management of coronary artery disease: therapeutic options in patients with diabetes J Am Coll Cardiol 36 2000 355 365
2. F. Mangiacapra, G. Patti, and A. Peace Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention Am J Cardiol 106 2010 619 623
3. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
4. M. Kazui, Y. Nishiya, and T. Ishizuka Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
5. J. Sahi, C.B. Black, and G.A. Hamilton Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition Drug Metab Dispos 31 2003 439 446
6. S.F. Zhou, C.C. Xue, and X.Q. Yu Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 2007 687 710
7. K.W. Park, J.J. Park, and K.H. Jeon Enhanced clopidogrel responsiveness in smokers: smokers' paradox is dependent on cytochrome P450 CYP1A2 status Arterioscler Thromb Vasc Biol 31 2011 665 671
8. J.A. Goldstein, T. Ishizaki, and K. Chiba Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations Pharmacogenetics 7 1997 59 64
9. J.A. Jakubowski, C.D. Payne, and Y.G. Li The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration Thromb Haemost 99 2008 409 415
10. M.J. Price, K.R. Nayak, and C.M. Barker Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol 103 2009 1339 1343
11. K.W. Park, J.J. Park, and K.H. Jeon Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans Cardiovasc Ther 30 2012 5 11
12. J. Mongan, H.Z. Mieszczanska, and B.H. Smith Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study Thromb Res 129 6 2012 760 764
13. W. Chokesuwattanaskul, Y. Yaqub, and J.A. Suarez Effect of pioglitazone on platelet aggregation in a healthy cohort Cardiology 116 2010 253 256
14. K.W. Park, K.H. Jeon, and S.H. Kang Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study) Am J Cardiol 108 2011 1556 1563